Loading stock data…
$0.61+0.00 (+0.66%)
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. in the Healthcare sector is trading at $0.61 with a market capitalization of $152M. Wall Street consensus targets $4.00 (5 analysts), implying a +555.7% move over the next 12 months. The stock is currently near its 52-week low of $0.50, remaining 43.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 19 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.47M↑ | $1.26M↓ | $1.50M↑ | $1.21M↑ | $1.16M |
| Gross Profit | $29,000↑ | -$369,000↓ | -$356,000↑ | -$486,000↓ | -$400,000 |
| Operating Income | -$12.80M↓ | -$12.11M↑ | -$14.01M↓ | -$11.76M↓ | -$11.38M |
| Net Income | -$11.69M↑ | -$13.91M↑ | -$16.27M↓ | -$10.40M↓ | -$4.44M |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, prima...